Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2023-03-29 Financial Supplement Da…
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Wybrane dane finansowe za 2022- podpis
Financial Supplement Data Classification · 95% confidence The document text consists entirely of XML digital signature blocks (ds:Signature) containing elements like SignedInfo, SignatureValue, KeyInfo, and references to external files (e.g., "Pharmena_wybrane_dane_finansowe_jedn_za_2022.xhtml"). This structure is characteristic of a digitally signed document, often used for regulatory filings or official reports to ensure authenticity and integrity. The presence of Polish issuer names ("Polska Wytwórnia Papierów Wartościowych S.A.") and references to financial data ("wybrane dane finansowe jedn za 2022") suggests a formal submission. Since the content is the signature metadata itself and not the narrative or structured data of a report (like 10-K, IR, or ER), and it is not a simple announcement of publication (RPA), the most appropriate general classification for a signed, official regulatory artifact that doesn't fit a specific report type is Regulatory Filings (RNS).
2023-03-29 Polish
Wybrane dane finansowe za 2022
Financial Supplement Data Classification · 95% confidence The document text consists entirely of structured financial data presented in tables, comparing figures (in thousands of PLN and EUR) for the 12-month periods ending December 31, 2022, and December 31, 2021. It includes key line items like Sales Revenue, Net Profit/Loss, Cash Flows, and Balance Sheet components (Assets, Liabilities, Equity). This format strongly suggests supplementary financial data, likely extracted from a larger report or provided in a structured data format for analysis. Given the options, 'Financial Supplement Data' (XLSX) is the most appropriate classification for raw, tabular financial figures, even if the input format here is text, as it represents the content type typically found in such supplements.
2023-03-29 Polish
List Prezesa Zarządu - podpis
Regulatory Filings Classification · 95% confidence The provided document text consists entirely of XML digital signature blocks (specifically XAdES signatures, indicated by namespaces like 'xmlns:ds' and 'xmlns:xades'). These signatures contain metadata about the signing process, certificates, and references to an external file named 'Pharmena_pismo_jedn_2022.xhtml'. This structure is characteristic of a digitally signed document, often used for regulatory compliance or official correspondence. Since the content is purely the signature wrapper and not the actual report content (like financial statements, management discussion, or meeting minutes), and it references a specific document ('pismo jedn' suggests a single official letter or document from 2022), the most appropriate classification is the general fallback for official regulatory filings that don't fit specific content categories, which is 'RNS' (Regulatory Filings). It is not an announcement of a report (RPA) because it is the signature block itself, which is often appended to the main filing.
2023-03-29 Polish
List Prezesa Zarządu
Management Reports Classification · 99% confidence The document is a letter from the Management Board ('W imieniu Zarządu Pharmena S.A. przedstawiam Państwu raport za 2022 rok') summarizing the company's performance for the year 2022, including revenue (20.05 mln zł), operating profit (1.13 mln zł), and net loss (4.05 mln zł). It discusses strategy, product portfolio expansion, R&D efforts (1-MNA drug), and outlook. This content strongly aligns with the Management Discussion and Analysis (MDA) section typically found in comprehensive annual or interim reports, focusing on management's explanation of results and trends. Since it is a summary/letter accompanying the full report, and it details operational and financial performance analysis, it fits the 'Management Reports' (MDA) category best, rather than being the full 10-K or just an Earnings Release (ER) which is usually shorter and focused only on key figures. Given the context of a year-end review, it is a management commentary on the annual performance.
2023-03-29 Polish
Przedłużenie istotnej umowy kredytowej z BGK - Content (PL)
Capital/Financing Update Classification · 98% confidence The document text, written in Polish, discusses an amendment (Aneks nr 7) to a revolving credit agreement (Umowy kredytu obrotowego) for Pharmena S.A., extending the credit line amount up to 2,000,000.00 PLN. This action relates directly to the company's financing activities and capital structure management (bieżącą płynnością finansową). Based on the definitions, this clearly falls under 'Capital/Financing Update' (CAP), as it details a change in a significant credit facility.
2023-03-01 Polish
Cesja praw i obowiązków z istotnych umów związanych ze sprzedażą produktów pod marką Menavitin - Content (PL)
Regulatory Filings Classification · 90% confidence The document is a formal announcement from the Management Board ("Zarząd") of Pharmena S.A. regarding a significant transaction: the assignment of rights and obligations related to the sale of the Menavitin trademark in Germany from a subsidiary (Menavitin GmbH) to the parent company, and the subsequent decision to write down the value of shares and loans to that subsidiary. This write-down impacts the parent company's individual financial statement for 2022 by PLN 4.94 million. This content relates to a significant business event and its financial impact, which is typical for regulatory disclosures concerning corporate structure changes, asset valuation adjustments, or material events affecting financial results. Since it details a specific transaction (cessation of subsidiary operations in a region) and its direct financial consequence (write-down), it fits best under Capital/Financing Update (CAP) if it were a fundraising event, or more generally as a significant corporate event disclosure. Given the nature of the transaction (restructuring/asset transfer) and the financial impact disclosure, it is a material event announcement. It is not a standard earnings release (ER), interim report (IR), or annual report (10-K). It is a specific disclosure about a material change in operations and asset valuation. In the context of the provided definitions, this type of material corporate action disclosure, especially one involving asset impairment due to restructuring, is often categorized under Capital/Financing Update (CAP) if it involves capital structure changes, or sometimes falls under Regulatory Filings (RNS) if no other specific category fits perfectly. However, since it details a significant operational restructuring and subsequent financial write-down, it is a material event disclosure. Given the options, and noting that it is not a standard financial report but a specific announcement of a material event impacting financials, it is closest to a general material disclosure. If the transaction involved raising capital or debt restructuring, CAP would fit. Since it involves asset impairment due to restructuring, and is a specific, material announcement, RNS (Regulatory Filings - fallback for miscellaneous material filings) is a strong candidate, but let's re-evaluate against CAP. CAP covers 'fundraising, financing activities, or capital structure changes'. The write-down is a consequence of restructuring, not fundraising. Therefore, RNS is the most appropriate fallback for a material, non-standard disclosure not covered by ER, IR, 10-K, or DIRS/DIV/etc.
2023-02-06 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.